Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers

Lukkana Suksanpaisan, Rong Xu, Mulu Z. Tesfay, Carolyn Bomidi, Stefan Hamm, Rianna Vandergaast, Nathan Jenks, Michael B. Steele, Ayuko Ota-Setlik, Hinna Akhtar, Amara Luckay, Rebecca Nowak, Kah-Whye Peng, John H. Eldridge, David K. Clarke, Stephen J Russell, Rosa Maria Diaz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms such as VSV. A major advantage of VSV expressing these antigens is that VSV also acts as an oncolytic virus, leading to direct tumor cell killing and induction of effective anti-E6 and anti-E7 T cell responses. We have also shown that addition of immune adjuvant genes, such as IFNβ further enhances safety and/or efficacy of VSV-based oncolytic immunovirotherapies. However, multiple designs of the viral vector are possible—with respect to levels of immunogen expression and method of virus attenuation—and optimal designs have not previously been tested head-to-head. Here, we tested three different VSV engineered to express a non-oncogenic HPV16 E7/6 fusion protein for their immunotherapeutic and oncolytic properties. We assessed their profiles of efficacy and toxicity against HPVPOS and HPVNEG murine tumor models and determined the optimal route of administration. Our data show that VSV is an excellent platform for the oncolytic immunovirotherapy of tumors expressing HPV target antigens, combining a balance of efficacy and safety suitable for evaluation in a first-in-human clinical trial.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalMolecular Therapy - Oncolytics
Volume10
DOIs
StatePublished - Sep 28 2018

Fingerprint

Antigens
Neoplasms
Oncolytic Viruses
Safety
Neoplasm Antigens
Therapeutics
Immunotherapy
Clinical Trials
Viruses
T-Lymphocytes
Genes
Proteins
Thomsen-Friedenreich antibodies

Keywords

  • HPV positive cancer
  • preclinical
  • VSV immunovirotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Suksanpaisan, L., Xu, R., Tesfay, M. Z., Bomidi, C., Hamm, S., Vandergaast, R., ... Diaz, R. M. (2018). Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers. Molecular Therapy - Oncolytics, 10, 1-13. https://doi.org/10.1016/j.omto.2018.05.001

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers. / Suksanpaisan, Lukkana; Xu, Rong; Tesfay, Mulu Z.; Bomidi, Carolyn; Hamm, Stefan; Vandergaast, Rianna; Jenks, Nathan; Steele, Michael B.; Ota-Setlik, Ayuko; Akhtar, Hinna; Luckay, Amara; Nowak, Rebecca; Peng, Kah-Whye; Eldridge, John H.; Clarke, David K.; Russell, Stephen J; Diaz, Rosa Maria.

In: Molecular Therapy - Oncolytics, Vol. 10, 28.09.2018, p. 1-13.

Research output: Contribution to journalArticle

Suksanpaisan, L, Xu, R, Tesfay, MZ, Bomidi, C, Hamm, S, Vandergaast, R, Jenks, N, Steele, MB, Ota-Setlik, A, Akhtar, H, Luckay, A, Nowak, R, Peng, K-W, Eldridge, JH, Clarke, DK, Russell, SJ & Diaz, RM 2018, 'Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers', Molecular Therapy - Oncolytics, vol. 10, pp. 1-13. https://doi.org/10.1016/j.omto.2018.05.001
Suksanpaisan, Lukkana ; Xu, Rong ; Tesfay, Mulu Z. ; Bomidi, Carolyn ; Hamm, Stefan ; Vandergaast, Rianna ; Jenks, Nathan ; Steele, Michael B. ; Ota-Setlik, Ayuko ; Akhtar, Hinna ; Luckay, Amara ; Nowak, Rebecca ; Peng, Kah-Whye ; Eldridge, John H. ; Clarke, David K. ; Russell, Stephen J ; Diaz, Rosa Maria. / Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers. In: Molecular Therapy - Oncolytics. 2018 ; Vol. 10. pp. 1-13.
@article{7865f98078d844a391b9e2307b931f29,
title = "Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers",
abstract = "Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms such as VSV. A major advantage of VSV expressing these antigens is that VSV also acts as an oncolytic virus, leading to direct tumor cell killing and induction of effective anti-E6 and anti-E7 T cell responses. We have also shown that addition of immune adjuvant genes, such as IFNβ further enhances safety and/or efficacy of VSV-based oncolytic immunovirotherapies. However, multiple designs of the viral vector are possible—with respect to levels of immunogen expression and method of virus attenuation—and optimal designs have not previously been tested head-to-head. Here, we tested three different VSV engineered to express a non-oncogenic HPV16 E7/6 fusion protein for their immunotherapeutic and oncolytic properties. We assessed their profiles of efficacy and toxicity against HPVPOS and HPVNEG murine tumor models and determined the optimal route of administration. Our data show that VSV is an excellent platform for the oncolytic immunovirotherapy of tumors expressing HPV target antigens, combining a balance of efficacy and safety suitable for evaluation in a first-in-human clinical trial.",
keywords = "HPV positive cancer, preclinical, VSV immunovirotherapy",
author = "Lukkana Suksanpaisan and Rong Xu and Tesfay, {Mulu Z.} and Carolyn Bomidi and Stefan Hamm and Rianna Vandergaast and Nathan Jenks and Steele, {Michael B.} and Ayuko Ota-Setlik and Hinna Akhtar and Amara Luckay and Rebecca Nowak and Kah-Whye Peng and Eldridge, {John H.} and Clarke, {David K.} and Russell, {Stephen J} and Diaz, {Rosa Maria}",
year = "2018",
month = "9",
day = "28",
doi = "10.1016/j.omto.2018.05.001",
language = "English (US)",
volume = "10",
pages = "1--13",
journal = "Molecular Therapy - Oncolytics",
issn = "2372-7705",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers

AU - Suksanpaisan, Lukkana

AU - Xu, Rong

AU - Tesfay, Mulu Z.

AU - Bomidi, Carolyn

AU - Hamm, Stefan

AU - Vandergaast, Rianna

AU - Jenks, Nathan

AU - Steele, Michael B.

AU - Ota-Setlik, Ayuko

AU - Akhtar, Hinna

AU - Luckay, Amara

AU - Nowak, Rebecca

AU - Peng, Kah-Whye

AU - Eldridge, John H.

AU - Clarke, David K.

AU - Russell, Stephen J

AU - Diaz, Rosa Maria

PY - 2018/9/28

Y1 - 2018/9/28

N2 - Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms such as VSV. A major advantage of VSV expressing these antigens is that VSV also acts as an oncolytic virus, leading to direct tumor cell killing and induction of effective anti-E6 and anti-E7 T cell responses. We have also shown that addition of immune adjuvant genes, such as IFNβ further enhances safety and/or efficacy of VSV-based oncolytic immunovirotherapies. However, multiple designs of the viral vector are possible—with respect to levels of immunogen expression and method of virus attenuation—and optimal designs have not previously been tested head-to-head. Here, we tested three different VSV engineered to express a non-oncogenic HPV16 E7/6 fusion protein for their immunotherapeutic and oncolytic properties. We assessed their profiles of efficacy and toxicity against HPVPOS and HPVNEG murine tumor models and determined the optimal route of administration. Our data show that VSV is an excellent platform for the oncolytic immunovirotherapy of tumors expressing HPV target antigens, combining a balance of efficacy and safety suitable for evaluation in a first-in-human clinical trial.

AB - Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms such as VSV. A major advantage of VSV expressing these antigens is that VSV also acts as an oncolytic virus, leading to direct tumor cell killing and induction of effective anti-E6 and anti-E7 T cell responses. We have also shown that addition of immune adjuvant genes, such as IFNβ further enhances safety and/or efficacy of VSV-based oncolytic immunovirotherapies. However, multiple designs of the viral vector are possible—with respect to levels of immunogen expression and method of virus attenuation—and optimal designs have not previously been tested head-to-head. Here, we tested three different VSV engineered to express a non-oncogenic HPV16 E7/6 fusion protein for their immunotherapeutic and oncolytic properties. We assessed their profiles of efficacy and toxicity against HPVPOS and HPVNEG murine tumor models and determined the optimal route of administration. Our data show that VSV is an excellent platform for the oncolytic immunovirotherapy of tumors expressing HPV target antigens, combining a balance of efficacy and safety suitable for evaluation in a first-in-human clinical trial.

KW - HPV positive cancer

KW - preclinical

KW - VSV immunovirotherapy

UR - http://www.scopus.com/inward/record.url?scp=85049426788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049426788&partnerID=8YFLogxK

U2 - 10.1016/j.omto.2018.05.001

DO - 10.1016/j.omto.2018.05.001

M3 - Article

VL - 10

SP - 1

EP - 13

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

SN - 2372-7705

ER -